Janux Therapeutics (JANX) Accounts Payables (2020 - 2026)
Janux Therapeutics (JANX) posted quarterly Accounts Payables of $3.4 million for Q1 2026, up 43.6% year-over-year from $2.4 million in Q1 2025, and down 32.09% quarter-over-quarter from $5.0 million in Q4 2025.
Janux Therapeutics (JANX) Accounts Payables (2020 - 2026) Analysis & Trends
Janux Therapeutics (JANX) has reported Accounts Payables for 7 consecutive years, with $3.4 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Accounts Payables rose 43.6% year-over-year to $3.4 million; the TTM figure through Mar 2026 stood at $3.4 million (up 43.6% YoY), while the FY2025 annual figure was $5.0 million, up 23.47% from the prior year.
- Accounts Payables retreated to $3.4 million in Q1 2026 per JANX's latest filing, from $5.0 million in the prior quarter.
- Across five years, Accounts Payables topped out at $5.0 million in Q4 2025 and bottomed at $1.3 million in Q2 2024.
- Historically, Accounts Payables has averaged $2.7 million across 5 years, with a median of $2.5 million in 2024.
- Annual changes were most pronounced in 2022 — Accounts Payables soared 747.46% — and 2023, when it slumped 36.33%.
- Janux Therapeutics' Accounts Payables stood at $2.2 million in 2022, then climbed by 12.27% to $2.4 million in 2023, then soared by 66.09% to $4.0 million in 2024, then climbed by 23.47% to $5.0 million in 2025, then slumped by 32.09% to $3.4 million in 2026.
- Business Quant data shows JANX's Accounts Payables at $3.4 million in Q1 2026, $5.0 million in Q4 2025, and $3.4 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Accounts Payables (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 429.50 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 1.16 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 1.52 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 88.42 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 470.30 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 3.05 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 35.57 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 108.02 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 428.93 Mn |
| 10 | Janux Therapeutics | 984.58 Mn | 984.58 Mn | - | 3.02 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 3.02 Mn |
| Mar 31, 2026 | 3.38 Mn |
| Dec 31, 2025 | 4.97 Mn |
| Sep 30, 2025 | 3.40 Mn |
| Jun 30, 2025 | 3.48 Mn |
| Mar 31, 2025 | 2.35 Mn |
| Dec 31, 2024 | 4.03 Mn |
| Sep 30, 2024 | 2.46 Mn |
| Jun 30, 2024 | 1.25 Mn |
| Mar 31, 2024 | 2.25 Mn |
| Dec 31, 2023 | 2.42 Mn |
| Sep 30, 2023 | 2.51 Mn |
| Jun 30, 2023 | 1.91 Mn |
| Mar 31, 2023 | 2.05 Mn |
| Dec 31, 2022 | 2.16 Mn |
| Sep 30, 2022 | 2.87 Mn |
| Jun 30, 2022 | 3.00 Mn |
| Mar 31, 2022 | 1.94 Mn |
| Dec 31, 2021 | 2.46 Mn |
| Sep 30, 2021 | 3.61 Mn |